Egetis Therapeutics: European Commission approves Emcitate - Redeye

Redeye endorses today’s news that the European Commission has approved Emcitate for “the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth” in the EU, which we also expected following the positive CHMP opinion in December. We see this as an important milestone for the company, now a commercial stage company, and look forward to follow the first launch in Q2. We will return with more thorough expectations in relation to our Q4 update later this month.

Länk till analysen i sin helhet: https://www.redeye.se/research/1076740/egetis-therapeutics-european-commission-approves-emcitate?utm_source=finwire&utm_medium=RSS